We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.9 for patients receiving a CD34+ cell dose <5 x 10(6) cells/kg versus 22,339.4+/- 5471.1 for those receiving >5 x 10(6) CD34+ cells/kg (p=0.0065).
F Baron, S Copizza, E Baudoux, G Jerusalem, G Fillet, Y Beguin. CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Haematologica 2004;89(9):1146-1148; https://doi.org/10.3324/%x.